Seattle Genetics Inc. said May 17 that it named Roger Dansey chief medical officer.
Dansey was most recently senior vice president at Merck & Co. Inc., where he was therapeutic area head for late-stage oncology. Before joining Merck, he worked at Gilead Sciences Inc. as vice president of oncology clinical research.
Dansey replaces Jonathan Drachman, who will continue to work with Seattle Genetics as a strategic adviser for innovation.
Bothell, Wash.-based Seattle Genetics is a biotechnology company that develops and sells targeted cancer therapies.